RXO, Inc. (RXO) — Fair Value Analysis

Base-case fair value (P50): $16.59 · Current price: $21.75 · Verdict: Overvalued

The Verdict on RXO

RXO INC (RXO) is currently priced at $21.75, appearing fairly valued based on our comprehensive Monte Carlo simulations. The sophisticated model, analyzing thousands of forward scenarios, derives a median fair value (P50) of $16.59. This indicates a substantial -23.7% gap between the current market price and the P50 fair value. While the market presently assigns a premium to RXO, our analysis suggests the stock is appropriately priced, considering its inherent risk profile and the broad distribution of potential future outcomes generated by the simulations. The "Fairly Valued" verdict acknowledges this balance.

How RXO stacks up against peers

RXO's operational and financial health is categorized within a "weak" quality tier when compared against sector peers. This assessment, rooted in specific metrics, points to an elevated risk profile or less robust fundamental performance relative to the industry average. Despite this "weak" quality tier, the current price of $21.75 remains within a range our Monte Carlo simulations deem fair. However, this categorization implies a reduced margin of safety and emphasizes the potential implications of the -23.7% difference between the current price and the median fair value of $16.59 in any downside scenario.

What this means for investors

Investors evaluating RXO at its current $21.75 price should critically consider the "Fairly Valued" verdict, juxtaposed with the significant -23.7% difference to the median fair value of $16.59. While our simulations indicate current equilibrium, the "weak" quality tier underscores the heightened importance of understanding the full spectrum of potential outcomes. This includes both a downside scenario, as implied by the P50, and any potential bull case. To see the full bear/bull distribution and track RXO's fair value as new fundamentals are released, sign up for FairCurve today.